Compare COGT & NEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | NEU |
|---|---|---|
| Founded | 2014 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.1B |
| IPO Year | 2018 | 2004 |
| Metric | COGT | NEU |
|---|---|---|
| Price | $39.57 | $787.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $36.21 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 101.5K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 12.62 |
| Revenue | $7,871,000.00 | ★ $2,725,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,733.58 | N/A |
| P/E Ratio | ★ N/A | $62.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.38 | $580.03 |
| 52 Week High | $43.73 | $875.97 |
| Indicator | COGT | NEU |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 49.59 |
| Support Level | $36.09 | $733.11 |
| Resistance Level | $40.67 | $778.99 |
| Average True Range (ATR) | 1.73 | 23.33 |
| MACD | -0.05 | 0.39 |
| Stochastic Oscillator | 65.50 | 63.95 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives used in lubricating oils and fuels to enhance performance. The company operates through two segments: petroleum additives, mainly represented by Afton, where lubricant additives improve the efficiency and durability of base fluids and fuel additives help meet fuel specifications and improve fuel performance, and specialty materials, represented by AMPAC and Calca, including the antiknock compounds business of Ethyl, where primary raw materials include electricity, sodium chlorate, ammonia, chlorine, caustic, and hydrochloric acid, with graphite used in electrolytic cells. The company has operations in North America, Latin America, Asia Pacific, and EMEAI regions.